Protamine Sulphate Inhibits Platelet Membrane Glycoprotein Ib-von Willebrand Factor Activity

Summary

Platelet adhesion to the injured vessel wall is essential in haemostasis and thrombosis. This process involves the interaction of the platelet glycoprotein Ib (GPIb) with surface bound von Willebrand factor (vWF). Since synthetic polycationic peptides of the general formula (Arg)n, (Lys)n or (Arg-Lys)n inhibit GPIb-vWF interaction, they were suggested as potential antithrombotics. Protamine sulphate is a highly cationic polypeptide, arginine accounting for approximately 60% of the primary sequence, utilized to neutralize the anticoagulant effect of heparin after cardiac surgery. We have investigated potential effects of protamine sulphate on the function of GPIb-vWF.

Addition of protamine sulphate to platelet-rich plasma (PRP), reduced significantly the GPIb-vWF activity as assessed by ristocetininduced platelet agglutination. When protamine sulphate was added to PRP containing heparin, even at clinically relevant neutralizing doses the GPIb-vWF activity was reduced by 20-30 % (p < 0.001). Protamine sulphate in excess of heparin nearly abolished the activity. Furthermore, the direct effect of protamine sulphate on collagen-induced platelet thrombus formation in non-anticoagulated human blood was investigated by employing an ex-vivo parallel-plate perfusion chamber device. Protamine sulphate (200 µg/mL) reduced platelet-collagen adhesion at shear rates of 650 and 2600 sec⁻¹ by 40% (p < 0.004) and 45% (p < 0.0001), respectively. The corresponding platelet thrombus volumes were concomitantly reduced by 90% (p < 0.006) and 84% (p < 0.05).

Our data are questioning the rationale for empirical repetitive protamine sulphate administration when so-called “heparin rebound” after cardiac surgery is suspected, since protamine sulphate in excess of heparin may impair the platelet GPIb-vWF interaction necessary for normal haemostasis.

Keywords

Protamine sulphate - platelet agglutination - glycoprotein Ib - von Willebrand factor - platelet adhesion - thrombus formation

Present addresses:

² Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark

³ Pharmacia & Upjohn AB, Department of Pharmacology, Uppsala and Stockholm, Sweden

• References

• 1 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature 1979; 279: 636-8.
• 2 Sakariassen KS, Fressinaud E, Girma JP, Meyer D, Baumgartner HR. Role of platelet membrane glycoprotein and von Willebrand factor in adhesion of platelets to subendothelium and collagen. Ann NY Acad Sci 1987; 516: 52-65.
• 3 Endenburg SC, Hantgan RR, Lindenboom-Blokzijl L, Lankhof H, Jerome WG, Lewis JC, Sixma JJ, de Groot PG. On the role of von Willebrand factor in promoting platelet adhesion to fibrin in flowing blood. Blood 1995; 86: 4158-65.
• 4 Bolhuis PA, Sakariassen KS, Sander HJ, Bouma BN, Sixma JJ. Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 1981; 97: 568-76.
• 5 Stel HV, Sakariassen KS, deGroot PG, van Mourik JA, Sixma JJ. von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90.
• 6 Kattlove HE, Gomez MH. Studies on the mechanism of ristocetin-induced platelet aggregation. Blood 1975; 45: 91-6.
• 7 Kroner PA, Frey AB. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis. Biochemistry 1996; 35: 13460-8.
• 8 Mohri H, Zimmerman TS, Ruggeri ZM. Synthetic peptides inhibit the interaction of von Willebrand factor-platelet membrane glycoproteins. Peptides 1993; 14: 125-9.
• 9 Subramaniam P, Skillington P, Tatoulis J. Heparin-rebound in the early postoperative phase following cardiopulmonary bypass. Austral & N Zeal J Surg 1995; 65: 331-3.
• 10 Shore-Lesserson L, Reich DL, DePiero M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaest 1998; 45: 10-8.
• 11 Yamanishi H, Watanabe S, Hayashi K, Tomioka H, Minami M, Nozaki Y, Aoki T, Kawai Y, Kishino K, Ohta S. A clinical evaluation of the Hepcon/HMS: a new device of monitoring hemostasis management during cardiopulmonary bypass. Jap J Thorac Surg 1997; 50: 459-62.
• 12 Sakariassen KS, Joss R, Muggli R, Kuhn H, Tschopp TB, Sage H, Baumgartner HR. Collagen type III induced ex vivo thrombogenesis in humans: role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 1990; 10: 276-84.
• 13 Sakariassen KS, Roald HE, Salatti A. Ex vivo models for studying thrombosis: special emphasis on shear dependent blood-collagen interactions. In: Hwang NHC, Turitto VT, Yen MRT. Advances in Cardiovascular Engineering. New York, NY: Plenum Press; 1992: 151-74.
• 14 Ørum E, Holen EÅ, Tangen G, Brosstad F, Abdelnoor M, Ringdal MAL, Øystese R, Istad R. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995; 60: 365-71.
• 15 Miller EF, Rhodes RK. Preparation and characterization of the different types of collagen. Methods Enzymol 1982; 82: 33-64.
• 16 Bruns RR, Gross J. High-resolution analysis of the modified quarter-stagger model of the collagen fibril. Biopolymers 1977; 13: 931-41.
• 17 Ørvim U, Barstad RM, Vlasuk GP, Sakariassen KS. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 2188-94.
• 18 Sakariassen KS, Muggli R, Baumgartner HR. Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol 1989; 169: 37-70.
• 19 Sakariassen KS, Kuhn H, Muggli R, Baumgartner HR. Growth and stability of thrombi in flowing citrated blood: assessment of platelet-surface interaction with computer-assisted morphometry. Thromb Haemost 1988; 60: 392-8.
• 20 Sobel M, Bird KE, Tyler-Cross R, Marques D, Toma N, Conrad HE, Harris RB. Heparins designed to specifically inhibit platelet interaction with von Willebrand factor. Circulation 1996; 93: 992-9.
• 21 Teoh KHT, Young E, Bradley CA, Hirsh J. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation. 1993 88. suppl II 420-5.